Adam Colborn of AMCP Gives a Legislative, Regulatory Update in the Pharmacy Space and Shares Concern on OOP Medicare Part D Copay Assistance | AMCP Nexus 2023

Part one of two

Adam Colborn, JD, director of Government Relations at AMCP, addressed topics at this year's AMCP Nexus in Orlando such as transparency, cost sharing mandates and variables that affect the supply and demand curve for pharmaceuticals within legislation at a federal, but mainly state level.

Colborn also touched on the large PBM reform regulation happening currently in New York as it could be a model that other states can follow.

In an interview with MHE, Colborn shared what AMCP is keeping their eyes on in terms of the IRA. He mentioned his team has shown concern over Medicare drug price negotiation and out-of-pocket "smoothing" or copay assistance for those under Medicare Part D.

Related: AMCP's Adam Colborn Talks Court Ruling's Impact on Employer Pharmacy Benefits and CalRX Insulin Cap | AMCP Nexus 2023

Colborn added the OOP "smoothing" is could be a large burden for retail and community pharmacists as they are the patient’s point of contact.

"It raises questions about 'how will a part D plan react if a patient changes their plan or they are unable to pay the rest of their prescription cost under a smoothing arrangement," he said. "It's a good first step but there are a lot of questions that still remain to be answered."